Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

NCT01514864 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy and slow accrual

Conditions

Carcinoma, Non-small Cell Lung

Interventions

DRUG: Dasatinib

Sponsor

Bristol-Myers Squibb